Sepsis. Update on pathophysiology, diagnostics and therapy;Sepsis. Aktuelle aspekte zu pathophysiologie, diagnostik und therapie

Anaesthesist

Volumn 55, Issue 8, 2006, Pages 835-845

  Bauer, M ^a   Brunkhorst, F ^a   Welte, T ^b   Gerlach, H ^c   Reinhart, K ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c VIVANTES KLINIKUM NEUKÖLLN   (Germany)

Author keywords

German Sepsis Society; Guidelines; Host response; Infection; Surviving Sepsis Campaign

Indexed keywords

ACTIVATED PROTEIN C; COMPLEMENT; HYDROCORTISONE; INTERLEUKIN 1; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ABDOMINAL INFECTION; ACINETOBACTER; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; ENTEROBACTER; ESCHERICHIA COLI; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; INTENSIVE CARE; KLEBSIELLA; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREVALENCE; PSEUDOMONAS; REVIEW; SEPSIS; SEPTIC SHOCK; STAPHYLOCOCCUS AUREUS;

ANIMALS; GERMANY; GUIDELINES; GUIDELINES AS TOPIC; HUMANS; IMMUNE SYSTEM; INFLAMMATION; SEPSIS;

EID: 33748506065     PISSN: 00032417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00101-006-1034-3     Document Type: Review

References (71)

1. Abraham E, Reinhart K, Opal S et al.; OPTIMIST Trial Study Group (2003) Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290(2): 238-247
2. ACCP/SCCM Consensus Conference Committee (1992) Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20(6): 864-874
3. Alberti C, Brun-Buisson C, Burchardi H et al.(2002) Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 28 (2): 108-121
4. Annane D, Sebille V, Charpentier C et al. (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288(7): 862-871
5. Bahrami S, Redl H, Yao YM, Schlag G (1996) Involvement of bacteria/endotoxin translocation in the development of multiple organ failure. Curr Top Microbiol Immunol 216: 239-258
6. Bateman RM, Sharpe MD, Ellis CG (2003) Bench-to-bedside review: microvascular dysfunction in sepsis-hemodynamics, oxygen transport, and nitric oxide. Crit Care 7(5): 359-373
7. Bates DW, Cook EF, Goldman L, Lee TH (1990) Predicting bacteremia in hospitalized patients. A prospectively validated model. Ann Intern Med 113(7): 495-500
8. Bates DW, Sands K, Miller E et al. (1997) Predicting bacteremia in patients with sepsis syndrome. Academic Medical Center Consortium Sepsis Project Working Group. J Infect Dis 176(6): 1538-1551
9. Bauer M, Paxian M, Kortgen A (2004) Akutes Leberversagen. Aktuelle Aspekte zur Diagnostik und Therapie. Anaesthesist 53: 511-530
10. Berghe G van den, Wouters P, Weekers F et al. (2001) Intensive insulin therapy in the critically ill patients. N Engl J Med 345(19): 1359-1367
11. Bernard GR, Vincent JL, Laterre PF et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344(10): 699-709
12. Bochud PY, Calandra T (2003) Pathogenesis of sepsis: new concepts and implications for future treatment. BMJ 326(7383): 262-266
13. Bockmeyer CL, Claus RA, Lösche W et al. (2005) Thrombotic microangiopathy (TMA) in patients with SIRS following open heart surgery - role of VWF cleaving protease ADAMTS13. Infection 33 [Suppl 1]: 16
14. Bone RC (1996) Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 24: 1125-1128
15. Brun-Boisson C, Roudot-Thoraval F, Girou E et al. (2003) The cost of sepsis syndromes in the intensive care unit and influence of hospital acquired sepsis. Intensive Care Med 29: 1464-1471
16. Brunkhorst FM, Eberhard OK, Brunkhorst R (1999) Discrimination of infectious causes of early acute respiratory distress syndrome by procalcitonin. Crit Care Med 27(10): 2172-2176
17. Brunkhorst FM, Wegscheider K, Forycki ZF, Brunkhorst R (2000) Procalcitonin for early diagnosis and differentiation of SIRS, sepsis, severe sepsis, and septic shock. Intensive Care Med 26 [Suppl 2]: S148-S152
18. Brunkhorst FM, Karzai W, Reinhart K (2002) Aktuelle Aspekte zur Sepsisdiagnose. Zentralbl Chir 127(3): 165-173
19. Brunkhorst FM, Engel C, Bone H-G et al. and the German Competence Network Sepsis (SepNet) (2005) Epidemiology of severe sepsis and septic shock in Germany - Results from the German Prevalence Study. Crit Care 9 [Suppl 1]: 83
20. Brunkhorst FM, Engel C, Jaschinsky U et al. and the German Competence Network Sepsis (SepNet) (2005) Treatment of severe sepsis and septic shock in Germany: the gap between perception and practice - result from the German Prevalence Study. Infection 33 [Suppl 1]: 49
21. Brunkhorst FM, Engel C, Welte T, Bloos F et al. and the German Competence Network Sepsis (SepNet) (2005) Prevalence of Infection in German intensive care units - Results from the German Prevalence Study. Infection 33 [Suppl 1]: 47
22. Brunkhorst FM, Kuhnt E, Engel C et al. and the German Competence Network Sepsis (SepNet) (2005) Intensive insulin therapy in patient with severe sepsis and septic shock is associated with an increased rate of hypoglycemia - results from randomized multicenter study (VISEP). Infection 33 [Suppl 1]: 19
23. Clec'h C, Ferriere F, Karoubi P et al. (2004) Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med 32(5): 1166-1169
24. Cobb JP (2001) Nitric oxide synthase inhibition as therapy for sepsis: a decade of promise. Surg Infect (Larchmt) 2(2): 93-100; discussion 100-101
25. Cobb JP, Buchman TG, Karl IE, Hotchkiss RS (2000) Molecular biology of multiple organ dysfunction syndrome: injury, adaptation, and apoptosis. Surg Infect (Larchmt) 1(3): 207-215
26. Creasey AA, Reinhart K (2001) Tissue factor pathway inhibitor activity in severe sepsis. Crit Care Med 29 [Suppl 7]: S126-129
27. Crowe M, Ispahani P, Humphreys H et al. (1998) Bacteraemia in the adult intensive care unit of a teaching hospital in Nottingham, UK, 1985-1996. Eur J Clin Microbiol Infect Dis 17(6): 377-384
28. Dellinger RP, Carlet JM, Masur H et al. (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 30: 536-555
29. Dempfle CE, Wurst M, Smolinski M et al. (2004) Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score. Thromb Haemost 91: 812-818
30. Engel C, Brunkhorst FM, Reinhart K, Löffler M and the German Competence Network Sepsis (SepNet) (2005) The SepNet Sepsis Prevalence Study: concept, design, and technical aspects of a nationwide cross-sectional survey on the epidemiology of sepsis in German ICUs. Infection 33 [Suppl 1]: 48
31. Engel C, Brunkhorst FM, Reinhart K, Löffler M and the German Competence Network Sepsis (SepNet) (2005) Incidence of sepsis in German ICUs - Results from the German Prevalence Study. Infection 33 [Suppl 1]: 50
32. Esmon CT (2004) Crosstalk between inflammation and thrombosis. Maturitas 47(4): 305-314
33. Garner JS, Jarvis WR, Emori TG et al. (1996) CDC definitions for nosocomial infections. In: Olmsted RN (ed) PIC infection control and applied epidemiology: principles and practice. Mosby, St. Louis, pp A1-20
34. Harbarth S, Holeckova K, Froidevaux C et al.; Geneva Sepsis Network (2001) Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 164(3): 396-402
35. Klinzing S, Simon M, Reinhart K et al. (2003) High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 31(11): 2646-2650
36. Kortgen A, Niederprüm P, Bauer M (2006) Implementation of an evidence-based "standard operating procedure" and outcome in septic shock. Crit Care Med 34: 943-949
37. Krueger WA, Lenhart FP, Neeser G et al. (2002) Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical trial. Am J Respir Crit Care Med 166(8): 1029-1037
38. Leibovici L, Greenshtain S, Cohen O et al. (1991) Bacteremia in febrile patients. A clinical model for diagnosis. Arch Intern Med 151(9): 1801-1806
39. Levi M, Jonge E de, Poll T van der (2004) New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med 36(1): 41-49
40. Levy GG, Nichols WC, Lian EC et al. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413: 488-494
41. Levy MM, Pronovost PJ, Dellinger RP et al. (2004) Sepsis change bundles: converting guidelines into meaningful change in behavior and clinical outcome. Crit Care Med 32 [Suppl]: S595-597
42. Marchetti O, Bille J, Fluckiger U et al. (2004) Fungal Infection Network of Switzerland. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends 1991-2000. Clin Infect Dis 38: 311-320
43. Marshall JC (2003) Such stuff as dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov 2(5): 391-405
44. Marshall JC, Christou NV, Meakins JL (1993) The gastrointestinal tract. The "undrained abscess" of multiple organ failure. Ann Surg 218(2): 111-119
45. Marshall JC, Cook DJ, Christou NV et al. (1995) Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 23(10): 1638-1652
46. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348(16): 1546-1554
47. Meisner M, Tschaikowsky K, Hutzler A et al. (1998) Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med 24(7): 680-684
48. Moake JL (2002) Thrombotic microangiopathies. N Engl J Med 347: 589-600
49. Moerer O, Schmid A, Hofmann M et al. (2002) Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med 28(10): 1440-1446
50. Müller B, Becker KL, Schächinger H et al. (2000) Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 28(4): 977-983
51. Müller-Berghaus G, Cate H ten, Levi M (1999) Disseminated intravascular coagulation: clinical spectrum and established as well as new diagnostic approaches. Thromb Haemost 82(2): 706-712
52. Osmon S, Warren D, Seiler SM et al. (2003) The influence of infection on hospital mortality for patients requiring >48 h of intensive care. Chest 124:1021-1029
53. Pannen BH, Robotham JL (1995) The acute-phase response. New Horiz 3(2): 183-197
54. Patel BM, Chittock DR, Russell JA, Walley KR (2002) Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 96(3): 576-582
55. Paxian M, Bauer I, Rensing H et al. (2003) Recovery of hepatocellular ATP and "pericentral apoptosis" after hemorrhage and resuscitation. FASEB J 17(9): 993-1002
56. Peres Bota D, Melot C, Lopes Ferreira F et al. (2002) The Multiple Organ Dysfunction Score (MODS) versus the Sequential Organ Failure Assessment (SOFA) score in outcome prediction. Intensive Care Med 28(11): 1619-1624
57. Reinhart K, Bayer O, Brunkhorst F, Meisner M (2002) Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 30 [5 Suppl]: S302-312
58. Rensing H, Bauer I, Zhang JX et al. (2002) Endothelin-1 and heme oxygenase-1 as modulators of sinusoidal tone in the stress-exposed rat liver. Hepatology 36(6): 1453-1465
59. Riedemann NC, Guo RF, Ward PA (2003) The enigma of sepsis. J Clin Invest 112(4): 460-467
60. Rivers E, Nguyen B, Havstad S et al.; Early Goal-Directed Therapy Collaborative Group (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345(19): 1368-1377
61. Sage WM, Rosenthal MH, Silverman JF (1986) Is intensive care worth it? An assessment of input and outcome for the critically ill. Crit Care Med 14(9): 777-782
62. Sakka SG, Reinhart K, Meier-Hellmann A (2002) Prognostic value of the indocyanine green plasma disappearance rate in critically ill patients. Chest 122(5): 1715-1720
63. Schaedler D, Schmitz G, Frerichs I et al. and the German Competence Network Sepsis (SepNet) (2005) How is mechanical ventilation employed in septic patients in Germany? - Results from the SepNet Prevalence Study. Infection 33 [Suppl 1]: 46
64. Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW (1988) Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 318(12): 727-732
65. Stüber A (2001) Effects of genomic polymorphisms on the course of sepsis: is there a concept for gene therapy? Am Soc Nephrol 12 [Suppl 17]: S60-64
66. Taylor FB Jr (1996) Role of tissue factor and factor VIIa in the coagulant and inflammatory response to LD100 Escherichia coli in the baboon. Haemostasis 26 [Suppl 1]: 83-91
67. Vincent JL, Bihari DJ, Suter PM et al. (1995) The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) study. EPIC International Advisory Committee. JAMA 274(8): 639-644
68. Vincent JL, Moreno R, Takala J et al. (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22(7): 707-710
69. Vincent JL, Abraham E, Annane D et al. (2002) Reducing mortality in sepsis: new directions. Crit Care 6 [Suppl 3]: S1-18
70. Wiedermann CJ, Kaneider NC (2004) Comparison of mechanisms after post-hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis. Ann Med 36(3): 194-203
71. Zeni F, Freeman B, Natanson C (1997) Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 25(7): 1095-1100